Sichuan Biokin Pharmaceutical Co (SHSE:688506) Long-Term Debt: ¥3,814 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688506 Sichuan Biokin Pharmaceutical Co Ltd SHSE:688506
79 GF Score
Price ¥238.62
GF Value ¥287.73
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Biokin Pharmaceutical Co Long-Term Debt?

Sichuan Biokin Pharmaceutical Co SHSE:688506 -2.86% 79 Long-Term Debt is ¥3,814 Mil as of Jun. 2026. GuruFocus rates SHSE:688506 with a GF Score™ of 79/100 and a GF Value™ of ¥287.73 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sichuan Biokin Pharmaceutical Co's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥3,814 Mil.

Sichuan Biokin Pharmaceutical Co's quarterly Long-Term Debt increased from Dec. 2025 (¥2,616 Mil) to Mar. 2026 (¥3,110 Mil) and increased from Mar. 2026 (¥3,110 Mil) to Jun. 2026 (¥3,814 Mil).

Sichuan Biokin Pharmaceutical Co's annual Long-Term Debt increased from Dec. 2023 (¥184 Mil) to Dec. 2024 (¥1,189 Mil) and increased from Dec. 2024 (¥1,189 Mil) to Dec. 2025 (¥2,616 Mil).

Sichuan Biokin Pharmaceutical Co  (SHSE:688506) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sichuan Biokin Pharmaceutical Co Long-Term Debt Related Terms

Sichuan Biokin Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sichuan Biokin Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Biokin Pharmaceutical Co Long-Term Debt Chart

Sichuan Biokin Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.00 239.96 183.92 1,189.43 2,615.96

Sichuan Biokin Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,572.13 2,810.09 2,615.96 3,110.49 3,814.45
SHSE:688506
79GF Score
Sichuan Biokin Pharmaceutical Co Ltd SHSE:688506
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥3,814 Mil mean?
Sichuan Biokin Pharmaceutical Co (SHSE:688506) has a Long-Term Debt of ¥3,814 Mil as of Jun. 2026.
Is Sichuan Biokin Pharmaceutical Co's Long-Term Debt too high?
Sichuan Biokin Pharmaceutical Co's current Long-Term Debt is ¥3,814 Mil. Overall, Sichuan Biokin Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Biokin Pharmaceutical Co's Long-Term Debt compare to ZTS?
Sichuan Biokin Pharmaceutical Co's Long-Term Debt of ¥3,814 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sichuan Biokin Pharmaceutical Co's current Long-Term Debt is ¥3,814 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Biokin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co (SHSE:688506) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥287.73, compared to a current price of ¥238.62 — trading 17.1% below its estimated fair value. The current Long-Term Debt is ¥3,814 Mil. Sichuan Biokin Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sichuan Biokin Pharmaceutical Co (SHSE:688506), the current Long-Term Debt is ¥3,814 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Biokin Pharmaceutical Co (SHSE:688506) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥238.62 is trading 17.1% below its estimated GF Value™ of ¥287.73. GuruFocus considers Sichuan Biokin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:688506:

  • Long-Term Debt: ¥3,814 Mil
  • GF Value™: ¥287.73 vs. price of ¥238.62 (17.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sichuan Biokin Pharmaceutical Co Business Description

Address No. 161, Baili Road, No. 1, Building 1, Cross-strait Science and Technology Industrial Park, Wenjiang District, Sichuan Province, Chengdu, CHN, 611130
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
79GF Score

Get the complete analysis for SHSE:688506

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥238.62
Price
¥287.73
GF Value